Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

Figure 13 Body weight changes with liraglutide are treatment dependent. Following the 56-wk treatment period a 12-wk follow-up (FUP) was conducted in SCALE maintenance, SCALE obesity and pre-diabeties and SCALE diabetes trials. Twelve weeks FUP was an off-treatment period in SCALE Maintenance and SCALE diabetes. In SCALE Obesity and pre-diabetes FUP period involved a re-randomisation to either 3 mg liraglutide (LIR/LIR) or placebo (LIR/Pl) and though weight gain occurred in all three groups weight gain was significantly higher following cessation of liraglutide. T2DM: Type 2 diabetes mellitus.